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CLINICO-PATHOLOGIC CHARACTERISTICS AND TREATMENT OUTCOMES 
IN CHILDREN WITH NEUROBLASTOMA AT THE KENYATTA NATIONAL 
HOSPITAL, NAIROBI
G. W. KITONYI, W. M. MACHARIA, O. W. MWANDA and R. PAMNANI
ABSTRACT
Objective: To determine clinical-pathologic characteristics, treatment modalities and 
treatment outcomes of children diagnosed with neuroblastoma. 
Design: Cross- sectional descriptive study based on secondary data from patient 
records. 
Setting: Records department of Kenyatta National Hospital (KNH), a tertiary teaching 
and referral hospital based in Nairobi. 
Subjects: Children aged 15 years and below, admitted with the diagnosis of 
neuroblastoma, between January 1997 and December 2005. 
Main outcome measures: Presenting clinical features, diagnostic modalities including 
laboratory and imaging data, treatment modalities, response to treatment and patient 
survival. 
Results: Twenty six patients were eligible for the study; 13 males and 13 females 
giving a M: F ratio of 1: 1. The age range was 5 days to 12 years, with a median age 
of five years. Abdominal swelling (53.8%), inability to walk due to bone pains, 
(50%), and cranial or periorbital swelling, (38.5%) were the commonest presenting 
features. Diagnosis of neuroblastoma was based on tissue biopsy in 50% (95% CI 
40.6-79.8%) of the patients, and on fine needle aspiration cytology of mass or bone 
marrow in the rest. Bone marrow involvement was present in 16, (75%). Anaemia, 
was common with 72.7% patients having a haemoglobin (HB) <8g/dl at presentation. 
Immunohistochemistry and cytological grading were done in two, (8%), patients. 
Urinary vanilly l mandelic acid (VMA), screening was positive in 50% (95% CI 29.9%-
70.1%). The most frequently involved organs were abdomen (88.9%), and skeleton, 
(84.6%). Majority of patients, (92.3%), presented with advanced stage IV disease. 
Three patients died before commencement of treatment. All treated patients (100%), 
received cytotoxic therapy. Only two patients (8.6%) had surgery as part of treatment 
while one, (4.3%) was treated with radiotherapy. The initial treatment regimen was 
similar for all the patients. Although most patients had a complete initial response to 
treatment, early relapse, treatment failure, death or loss to follow up of patients with 
progressive disease were common. Overall survival (OS) at one year and two years 
were 19.2% (95% CI 6.6-39.4%) and 7.7% (95% CI 0.9%-25 1%) respectively. Only one 
patient was alive, (also free of disease), five years after diagnosis. 
Conclusion: Although other clinical- pathologic findings of the patients were similar 
to those reported elsewhere, virtually all study patients presented with advanced stage 
IV disease, which would be associated with poor prognosis irrespective of quality of 
care. Priority must therefore be on ensuring early diagnosis and referral of patients 
with neuroblastoma before any other interventions can be expected to positively impact 
on outcome. The limited role of surgery and radiotherapy observed over the study 
period may be attributed to late presentation of the patients. Pathologic evaluation of 
patients was inadequate, to some extent due to unavailability of facilities, but extra 
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INTRODUCTION
Neuroblastoma, a malignant childhood embryonal 
tumour of the sympathetic neuroblasts is the most 
common extra- cranial solid childhood tumour in 
the developed world, making up 8% of all malignant 
neoplasms in children (1).The tumour arises from sites 
where these tissues are distributed and spreads by 
contiguous extension, haematogenous or lymphatic 
tissues spread. Common metastatic sites are the liver, 
bone marrow and skin. Although neuroblastoma is 
less common in African children, a significant number 
of children are diagnosed with neuroblastoma each 
year, leading to considerable morbidity and mortality. 
In a study involving 787 cases of childhood cancers at 
KNH, (excluding retinoblastoma and brain tumours), 
Macharia(2)  found a relative neuroblastoma 
frequency of 3.3%. 
 Over half of neuroblastoma patients present 
before or at the age of two years. Rarely, neuroblastoma 
maybe congenital. Patients commonly present with 
abdominal swelling, orbital and periobital masses, 
manifesting as proptosis, exophthalmos, and 
periorbital oedema. Bone and joint pains, walking 
difficulties, and inability to stand, occur due to 
skeletal infiltration. Bone marrow involvement is 
present in over half of all patients at presentation, 
leading to anaemia and occasional thrombocytopenia. 
Neurological symptoms may arise from cord 
compression or cranial extension of the tumour. A 
proportion of patients present with chest tumours, 
at times giving rise to superior vena caval syndrome. 
Rarely, Horner’s syndrome may be encountered when 
there is neck involvement. In neonates subcutaneous 
nodules are sometimes present. Non specific clinical 
features include irritability, lassitude, weight loss, 
fever, vomiting and diarrhoea. Symptoms associated 
with catecholamine production and vasoactive 
intestinal polypeptide syndrome maybe present in 
occasional patients (1). 
 Ideally all neuroblastoma patients should have 
tissue biopsy and histopathology diagnosis, which 
should include morphological grading of the tumour 
as either high risk, (associated with poor prognosis), 
or low risk (3). Neuroblastomas are generally 
small round blue cell tumours which sometimes 
exhibit pseudorossete formation. In histology 
and cytology materials, some neuroblastomas 
may be indistinguishable from other small 
round blue cell tumours. In these difficult cases 
immunohistochemistry (4) and measurement of 
catecholamine metabolites vanillymandelic acid 
(VMA) or homovanilylmadelic acid (HVMA), are 
useful in arriving at a firm diagnosis. VMA and 
HVA have been reported as positive in up to 90% 
of patients with highly sensitive chromatographic 
tests (5). Measurement of VMA is helpful in resource 
limited set ups where immunohistochemistry maybe 
prohibitively expensive. VMA can also be used for 
monitoring therapy. Molecular defects of prognostic 
value in neuroblastoma include the MYCN oncogene 
over expression, present in about 25% of patients. 
Over expression of MYCN overexpression is a 
poor prognostic indicator (6). Elevation of serum 
ferritin, neurone specific enolase, (NSE), and lactate 
dehydrogenase, (LDH), have been associated with 
poor prognosis, and would be particularly useful 
in centres without facilities to undertake molecular 
studies. While LDH and serum ferritin are useful 
for disease monitoring response to treatment, NSE 
maybe useful in the differentiation of stage IVs from 
Stage IV, as the latter is associated with much higher 
levels (7). 
 Disease stage and age at presentation are the most 
important predictors of prognosis of neuroblastoma 
(l,8). Indeed countries such as Japan, Canada, USA and 
United Kingdom have previously carried out VMA 
screening programmes in children below the age of 
one year, using highly sensitive chromatographic 
techniques, with the aim of detecting early, sub clinical 
neuroblastoma to improve prognosis. Although the 
value and cost effectiveness of these mass screening 
programmes remain controversial, this illustrates the 
prognostic importance placed on early detection of 
neuroblastoma (1). The International Neuroblastoma 
Staging System, (INSS), is one of the most widely used 
methods of staging neuroblastoma (6). Advanced 
disease particularly stage IV is associated with very 
poor prognosis while localised stages I, II, has very 
favorable prognosis (3). 
 In the developed world, about 55% of 
neuroblastoma patients present with advanced poor 
prognosis stage VI disease. Infants aged one year and 
below, have a very good prognosis with cure rates 
as high as 80% reported, even with advanced Stage 
IVS disease (1,8). 
 Current ly  pa t ien ts  d iagnosed  wi th 
neuroblastoma in developed countries are stratified 
into three major risk groups; the low risk category, 
intermediate risk and a high risk category. Patients 
with localized Stages I and II disease, favorable 
histology, and without MYCN amplification are 
important information could have been availed at minimal extra cost. To be at par with 
current internationally accepted treatment approaches that have been associated with 
improved survival, there is need to base choice of regimens for individual patients on 
clinical and readily accessible pathologic markers. 
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classified as low risk. Infants below one year 
are also included in the low low risk category 
including those with Stage VIS disease. Treatment 
of this low risk group includes radical surgical 
excision of tumour, low intensity chemotherapy 
and radiotherapy in some patients (1). Criteria for 
high risk assignment include advanced stage IV 
disease, presence of MYCN gene amplification and 
age above one year. These high risk patients are 
treated with high intensity and myelosuppressive 
therapy which may necessitate bone marrow rescue 
with haemopoietic cell transplants. Intermediate 
risk patients may have some features of low risk 
and high risk categories, and are treated with 
intermediate intensity chemotherapy generally. 
Novel therapies include targeted radiotherapy 
and immunotherapy. This risk adapted treatment 
approach of neuroblastoma which matches clinical 
-pathologic features with treatment modality has 
yielded very significant improvement in survivals 
of neuroblastoma patients in the developed world. 
Event free survival of up to 90% has been reported 
in the low risk groups. Up to 40 -60% long term 
survivals in the intermediate and low risk groups 
(6) are being achieved. These superior treatments 
outcomes are a result of continuous reviews and 
updates of treatments which are carried out every 
two years or so. Such frequent reviews maybe 
unaffordable in resource limited set ups. However 
efforts should nevertheless be made to carry out the 
reviews about every five years. 
 In Kenya, the last review on neuroblastoma 
treatment outcomes, but which did not even include 
clinical-pathologic features, was carried out by Kasili 
et al  (9) over 20 years ago. The present study was 
carried out to determine both clinical-pathologic 
characteristics and treatment outcomes in children 
admitted for neuroblastoma treatment at KNH. The 
findings of this study may be useful in renewing 
attention to presentation and management status of 
this childhood malignancy whose local importance is 
often overshadowed by the more prevalent childhood 
malignancies like lymphomas, nephroblastoma and 
leukemia’s. 
MATERIALS AND METHODS
Study design, setting and subjects: This was a cross- 
sectional descriptive study based on review of 
patients’ records. The study period was January 1997 
to December 2005. Records of all children  aged 15 
years and below, with the diagnosis of neuroblastoma, 
were retrieved and data extracted using pre-designed 
data extraction sheets. 
Case definition: Only subjects with a histopathology 
or cytology, (tumour, bone marrow or both), 
diagnosis consistent with neuroblastoma were 
eligible for inclusion. Cases with clinical features of 
neuroblastoma, but doubtful histology or cytology, 
were included if the urinary VMA was positive. 
Data collection: All records of eligible patients were 
retrieved and scrutinised. Information on age at 
presentation, sex, presenting complaint(s) and 
duration, which included presence of swelling and 
their sites, pain and inability to walk, evidence 
of neurological disease, non specific signs and 
symptoms, (such as weakness, fever, diarrhoea, 
vomiting, irritability, and excessive sweating) were 
captured and recorded in pre-designed data extraction 
sheets. Laboratory data including full blood counts, 
clinical chemistry, (liver function and kidney function 
tests, LDH, ferritin, uric acid and urinary VMA 
screening results, histopathology reports, FNA and 
bone marrow cytology reports were also recorded. 
Diagnostic imaging results, (chest X-rays, skeletal 
surveys, abdominal ultrasound, CT scans and MRI 
reports), were also recorded. Staging of disease 
was noted and recorded, and where not indicated 
retrospective staging done according to the INSS. 
Treatment and treatment modalities were included. 
For patients who had surgery, the type and reason 
for surgery was also extracted. Where chemotherapy 
was given, the protocol, number of courses given 
and completed was recorded. Response to treatment 
was classified as complete, partial, minor or none. 
Patients who got radiotherapy and their response 
to radiotherapy were noted. Survival was measured 
from the time the patient was first seen at KNH, to the 
last time they were seen alive with or without disease. 
Where patients were lost to follow up with progressive 
disease, or transferred to the nearest hospital with 
unresponsive disease, this was also noted. 
Data analysis: The data was computerised cleaned and 
verified using the SPSS version 10.0 software. Analysis 
was basically frequency analysis, giving rise to median 
and descriptive proportions. Baseline characteristics 
were tabulated and frequency of variables calculated. 
Ninety five per cent Confidence intervals were 
calculated for primary outcome measures to indicate 
accuracy of the estimates. P-values of less than 0.05 
were considered as significant. Overall survival was 
calculated from the date of admission to the date of last 
follow up when status, (dead or alive) with presence 
or absence of malignant disease also noted. 
RESULTS
Although 57 patient’s files had a diagnosis of 
neuroblastoma, 31 cases were excluded from 
analysis because either the diagnosis was equivocal 
or the records were incomplete, leaving 26 cases. 
Age range was 5 days to 12 years, the median age 
five years. As shown in Table 1, 50% of the patients 
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were aged two years and below. Male: Female 
ratio was 1:1, with 13 males and 13 females. Table 
2 summarises the presenting features and shows 
that the commonest presenting features were 
abdominal swelling 14, (53.8%), inability to walk 
due to bone pains,13, (50%), and head or orbital 
swellings, 10, (38.5%). Over half of the patients had 
non specific symptoms, such as, fever, vomiting, 
irritability, diarhoea and fatigue. Based on clinical, 
laboratory and diagnostic imaging, the abdomen 
(88.9%); skeleton (84.6%), bone marrow (75%) 
Table 1
Distribution of neuroblastoma patients at presentation by age and gender (n=22)
Age (years) Male  Female  Total (%) Cumulative (%)
> 1 4 3 7 31.8 31.8
1 - 2 3 1 4 18.2 50
3 - 6  0 3 3 13.6 63.6
7 - 10  1 3 4 18.2 81.5
11-15  3 1 4 18.2 100
Total  11 11 22 100
NB: The age was not clearly indicated in the records of four patients
 
Table 2
Presenting clinical features in 26 children with neuroblastoma
Clinical feature  No. of patients  (%) of total 
Abdominal swelling  14  53.8 
Inability to walk and bone pains  13  50 
Swellings on the head and proptosis  10  38.5 
Fever  5  19.8 
Weakness  4  15.4 
Vomiting  3  11.5 
Sweating  2  7.7 
Swellings elsewhere (testis and femur)  2  7.7 
Others (one each)*  3  11.5 
*Diarrhoea, convulsions and superior vena caval syndrome 
Note: Some patients had more than one presenting symptoms 
and the head and neck (36.8%) were the most 
frequently involved sites as seen in Figure 1. In 
Table 3 it is noted that most patients, 24, (92.3%) 
presented with advanced stage IV disease. Table 
4 shows laboratory characteristics at presentation. 
Anaemia was common with 16, (72.7%) patients 
having an Hb equal to or less than 8g/dl. Bone 
marrow involvement was present in 12 out of 16 
(75%) patients examined. One patient presented 
with an isolated testicular mass, whose diagnosis 
was confirmed with immunohistochemistry. 
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Table 3
Disease stage at presentation in 26 children with neuroblastoma according to the International Neuroblastoma 
Staging System
Stage No. of patients % of patients Staging criteria 
I 0 0 Localised tumour with complete gross excision, 
with or without microscopic residual disease: 
representative ipsilateral lymph nodes negative for 
tumour  microscopically, (nodes attached to and 
removed with the tumour maybe positive)
IIA 0 0 Localised tumour with or without complete gross 
excision with ipsilateral non-adherent lymph nodes 
negative for tumour. Enlarged contra-lateral lymph 
nodes must be negative tumour microscopically
IIB 1 3.8 Localised tumour with or without complete excision, 
with ipsilateral nonadherent lymph nodes positive 
for tumour. Enlarged Contra- lateral lymph nodes 
must be negative microscopically
III 0 0 Unresectable unilateral tumour infiltrating across 
the midline, with or without regional lymph node 
involvement; or localised unilateral tumour with 
contra- lateral regional lymph node involvement: or 
midline tumour with bilateral extension by infiltration 
(unresectable) or by lymph node involvement   
IV 24 92.3 Any primary tumour with dissemination to distant 
lymph nodes, bone, bone marrow, liver, skin or 
other organs (except Stage 4S*)
IVS 1 3.8 Localised primary tumour as defined for stages 1, 2A 
or 2B, with dissemination limited to skin, liver, and 
or bone marrow involvement (10% involvement)
Table 4
Laboratory characteristics of children with neuroblastoma before commencement of treatment
Characteristic  No.   (%) 
Hb* level (g/dl) 
  8.0 - 5.0  16    72.7 
Bone marrow cytology done  16    72.7
  Bone marrow involvement among those  12    75.0 
  Who had bone marrow aspiration 
FNA-C** of tumour done 18    81.8
  Positive for neuroblastoma  16    72.7 
Tissue biopsy for diagnosis (n= 16) 8     50 
  Number who had histological grading  2     12.5
  Number who had immunohistochemistry  2     12.5 
Urinary screening for VMA ***  12    54.5
 Number with positive VMA  6     50.0 (of those tested) 
Number whose LDH level was tested  3     13.6 
  Number with elevated LDH  3     100 (of those tested) 
* Hb = Haemoglobin. The lowest Hb was 5.4g/dl 
**FNAC = Fine needle aspirate cytology 
***VMA = Vanilyl mandelic acid 
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Figure 1
Frequency of involvement of various body sites at presentation 
Table 5
Results of imaging in children with neuroblastoma, ( before treatment)
Mode of imaging Number with (%)  Type of abnormality
 abnormal findings 
  
CXR (n=12) 10 83 Pneumonic changes, (n=4)
   Mediastinal masses (n=3)
   Lytic lesions (n=2)
   Pleural effusion (n=1)
Abdominal (n=14)
  ultrasound 13 92.9 Complex and other abdominal masses and 
enlarged para-aortic nodes (n=7)
   Suprarenal masses (n=4)
   Liver metatasis (n=3)
Skeletal X-rays (n=8)
  (excluding chest) 8 100 Lytic lesions (n=8)
   Expanding masses (n=2)
   Sutural diastasis (n=1)
IVUs (3) 3 100 Suprarenal mass (n=2)
   Retroperitoneal mass (n=1)
CT Scans 4 100 Destructive orbital mass (n=1)
   Intracranial tumour (n=1)
   Thoracis mass (n=1)
   Liver metastasis (n=1) 
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Urinary VMA screening using visual colour change 
method, was positive in 50% (CI 29.9- 70.1 %), of 
the patients who were screened. LDH was elevated 
in all the four patients for whom it was done, 
(at diagnosis) and results were available. None 
of the patients had serum ferritin or NSE levels 
estimated. Liver transaminases were elevated in 
two patients, one of whom had a positive hepatitis 
B surface antigen. Renal functions were normal 
in all patients. Histopathology was the basis for 
diagnosis in 50% (CI 40.6-79.80%) patients’ records 
available, while the rest had a diagnosis based on 
FNA of tumour or bone marrow cytology together 
with VMA findings. Two patients, (8%), who had 
difficult histology, had confirmation of diagnosis by 
immunohistochemistry done in a foreign country. 
These two histologies also had histological grading 
indicated on the reports carried out overseas. 
Amongst the 12 patients who had FNA cytology, two 
also had tissue biopsy and in these cases cytology 
and histopathology results concurred. Table 5 
summarises the types and results of the patient’s 
imaging. Abnormal imaging results were present 
in majority of the patients. 
Table 6
Treatment outcome and survival of neuroblastoma 
patients
Response to treatment (n=19*) No. (%)
Complete initial response, 
(>90% decrease in tumour size) 7  42.1
Partial response  5 26.3
(50-90% decrease in tumour size) 
Minor or no response  6 31.6
(>25% reduction in tumour size) 
Total  19 100
Survival of 26 neuroblastoma patients 
with or without treatment 
  Died within 6 months**  16 61.5
  Survived up to 1 year  5 19.2
  Survived up to 2 years  2 7.7
  Survived up to 5 years  1 3.8
* Three patients died before commencement of 
treatment 
** Includes two patients lost to follow up with 
progressive terminal disease, presumed dead 
Table 6 shows treatment response and survival 
of the patients. Three very ill patients died before 
treatment commencement. The rest of the patients 
all (100%) underwent combination chemotherapy 
with vincristine, cyclosphosfamide, adriamycin 
and cis- platin by either one of 2 protocols (10, 11). 
Radiotherapy was given to only one patient who 
had a complex pelvic mass compressing the ureters 
and causing hydronephrosis, a hydrocoele and 
renal failure. The tumour responded favorably to 
radiotherapy initially with partial regression of the 
tumour. However recurrence at the same site within 
a few weeks, led to death of the patient from renal 
failure. 
 Majority of the patients had initial complete or 
partial response to chemotherapy. However most had 
subsequent relapse and resistance to chemotherapy 
and either died or were discharged with progressive 
disease. Overall survival at one and two years was 
19.2% (CI 6.6- 39.4%) and 7.7% (CI 0.925 - 25.1%) 
respectively. Only one patient, (3.8%), who had 
presented with stage 2B disease, survived, (also 
disease free) beyond five years (3.8%). 
DISCUSSION
The clinical presentation of patients in this study are 
very similar to what has been described elsewhere 
in both developed and developing countries (3, 6, 
12). The youngest patient presented at KNH with 
anaemia and abdominal distension at the age of five 
days. According to the history, abdominal masses and 
anaemia were noted soon after birth. Most probably 
this patient had congenital neuroblastoma. Half of 
the patients were aged two years and below. The 
commonest presenting features included swellings 
of the abdomen, inability to walk due to bone pains 
and non specific symptoms such as weakness, fever, 
vomiting and sweating. The most frequently involved 
sites were the abdomen, skeleton, head and neck. Bone 
marrow involvement and anaemia were frequent. 
These findings are comparable with what is reported 
in the literature (1,3,13). 
 However  majority presented with advanced 
stage IV disease. One unusual case was a patient 
who presented with an isolated testicular swelling, a 
rare finding in neuroblastoma (1). Despite complete 
excision of the tumour, followed by chemotherapy and 
radiotherapy, there was aggressive tumour regrowth 
with compression of the ureters, renal failure and 
death of the patient. 
 Ideally all patients with neuroblastoma should 
have a tissue diagnosis in which the risk category 
is indicated to guide in the decision of appropriate 
intensity of treatment (1). Half of the patients whose 
data was available did not have tissue diagnosis. To 
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improve our treatment outcomes of neuroblastoma, it 
will be necessary to ensure that all patients suspected 
to have neuroblastoma have tissue biopsy, not only 
to improve the accuracy of diagnosis, but to also help 
with risk categorisation and possible risk adaptation 
of the treatment. 
 Only half of patients whose records could be 
evaluated had VMA screening. Expensive techniques 
like immunohistochemistry may not be affordable in 
public hospitals in Kenya but it is recommended that 
more affordable tests like a sensitive VMA test and 
serum ferritin be made readily available to improve 
on the diagnosis of neuroblastoma in resource 
constrained set ups. 
 Although surgery and radiotherapy have 
important roles in treatment of neuroblastoma 
(12), only one patient had surgery as a debulking 
procedure in this study. This patient had the best 
prognosis. Radiotherapy was given to only one patient 
as a palliative measure. The limited role of surgery 
and radiotherapy is most likely related to the late 
presentation of the patients in this study. 
 Over 20 years back, Kasili et al (9) noted that 
neuroblastoma had the poorest prognosis of all 
paediatric solid tumours managed at the KNH. He also 
noted that this was associated with late presentation 
of patients. The prognosis of neuroblastoma remains 
very poor compared to the greatly improved results 
recorded by developed countries (1, 3, 9). As long as 
patients continue to present with advanced disease, 
the prognosis of neuroblastoma is likely to remain 
poor irrespective of the quality of care or any other 
interventions. 
 A significant limitation of this study was the small 
number of subjects that met eligibility criteria because 
of missing data. This is however not surprising with 
a retrospective study. A prospective study is therefore 
recommended which should avail more precise 
information. 
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